Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial

医学 类风湿性关节炎 内科学 Janus激酶抑制剂 临床终点 安慰剂 随机对照试验 外科 托法替尼 病理 替代医学
作者
R. Fleischmann,Alan Friedman,Edit Drescher,Atul Singhal,Gregorio Cortes-Maisonet,Thao Doan,Wenjing Lü,Zailong Wang,Ahmed Nader,William Housley,Stanley Cohen,Peter C. Taylor,Ricardo Blanco
出处
期刊:The Lancet Rheumatology [Elsevier BV]
卷期号:4 (6): e395-e406 被引量:9
标识
DOI:10.1016/s2665-9913(22)00092-3
摘要

Background ABBV-599 is a novel fixed-dose combination of the Bruton's tyrosine kinase (BTK) inhibitor elsubrutinib and the Janus kinase (JAK) inhibitor upadacitinib under investigation for the treatment of autoimmune diseases. We aimed to determine whether ABBV-599 could increase the treatment response for patients with active rheumatoid arthritis compared with inhibiting either pathway alone, while maintaining an acceptable safety profile. Methods We conducted a multicentre, double-blind, parallel-group, dose-exploratory, randomised, controlled, phase 2 trial at 75 community sites in eight countries in Europe and North America. We enrolled patients who were 18 years or older with rheumatoid arthritis and inadequate response or intolerance to biological disease-modifying antirheumatic drugs. Eligible patients were randomly assigned (3:2:2:2:2:1) via interactive response technology to receive daily, orally administered ABBV-599 (ie, upadacitinib 15 mg plus elsubrutinib 60 mg), elsubrutinib 60 mg, elsubrutinib 20 mg, elsubrutinib 5 mg, upadacitinib 15 mg, or placebo. Randomisation was stratified by the number of previous biological disease-modifying antirheumatic drugs. The investigator, study site personnel, and patients were masked throughout the study. The primary endpoint was change from baseline in disease activity score of 28 joints with C-reactive protein (DAS28-CRP) at week 12 for all patients who received a study drug. Pharmacokinetics and safety were also assessed. This study is registered with ClinicalTrials.gov, number NCT03682705. Findings Between Oct 8, 2018, and March 26, 2020, 242 patients were randomly assigned to receive ABBV-599 (n=62), elsubrutinib 60 mg (n=41), elsubrutinib 20 mg (n=39), elsubrutinib 5 mg (n=41), upadacitinib 15 mg (n=40), or placebo (n=19). Of the 242 patients, 204 (84%) were female, 38 (16%) were male, and 220 (91%) were White; the mean age at baseline was 58·0 years (SD 11·3). Compared with placebo, the least squares mean changes from baseline in DAS28-CRP were –1·44 (90% CI –2·03 to –0·85; p<0·0001) for ABBV-599, –0·40 (−1·03 to 0·23; p=0·29) for elsubrutinib 60 mg, –0·20 (−0·85 to 0·44; p=0·61) for elsubrutinib 20 mg, –0·21 (−0·84 to 0·41; p=0·57) for elsubrutinib 5 mg, and –1·75 (−2·38 to –1·13; p<0·0001) for upadacitinib. No significant improvements in efficacy measures for elsubrutinib alone (any dose) versus placebo were detected, despite adequate plasma exposure and target engagement. Treatment-emergent adverse events were observed in 113 (47%) of 242 patients, with similar proportions for all groups. Interpretation Significant improvements in disease activity metrics of rheumatoid arthritis with ABBV-599 were driven by the JAK inhibitor upadacitinib with no discernible effect by the BTK inhibitor elsubrutinib. Funding AbbVie.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
二马三乡完成签到 ,获得积分10
刚刚
1秒前
木野狐发布了新的文献求助10
4秒前
喂喂完成签到 ,获得积分10
6秒前
7秒前
干净问筠完成签到,获得积分10
8秒前
kang发布了新的文献求助10
9秒前
10秒前
10秒前
荷子完成签到,获得积分20
12秒前
12秒前
12秒前
12秒前
14秒前
15秒前
ReBorn发布了新的文献求助10
15秒前
裴仰纳完成签到 ,获得积分10
16秒前
傲娇蓝血发布了新的文献求助30
16秒前
16秒前
撒西不理给撒西不理的求助进行了留言
17秒前
路灯下的小伙完成签到,获得积分10
17秒前
zym999999发布了新的文献求助10
20秒前
Jrssion发布了新的文献求助10
20秒前
夏惋清完成签到 ,获得积分0
21秒前
量子星尘发布了新的文献求助10
22秒前
ClaudiaCY发布了新的文献求助150
22秒前
kang完成签到,获得积分20
24秒前
天才臭屁星完成签到 ,获得积分10
25秒前
Ava应助粱涵易采纳,获得10
25秒前
Jasper应助Literaturecome采纳,获得10
26秒前
sci发布了新的文献求助10
26秒前
卜大大发布了新的文献求助10
27秒前
冷万天关注了科研通微信公众号
27秒前
seal发布了新的文献求助10
28秒前
29秒前
31秒前
念之完成签到 ,获得积分10
33秒前
35秒前
Ljc发布了新的文献求助10
36秒前
拼搏的宇完成签到,获得积分10
37秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3958051
求助须知:如何正确求助?哪些是违规求助? 3504213
关于积分的说明 11117431
捐赠科研通 3235582
什么是DOI,文献DOI怎么找? 1788318
邀请新用户注册赠送积分活动 871204
科研通“疑难数据库(出版商)”最低求助积分说明 802511